The FDA is making plans to allow overseas baby formula makers to keep selling their products in the U.S. long term
Federal health regulators are devising plans that would let overseas baby formula makers market their products in the U.S. long term beyond the currentTo ease shortages of baby formula, the Food and Drug Administration has been temporarily allowing foreign manufacturers.
Federal health regulators are devising plans that would let overseas baby formula makers market their products in the U.S. long term beyond the currentTo ease shortages of baby formula, the Food and Drug Administration has been temporarily allowing foreign manufacturersSingapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Serious Illnesses From Daily Harvest Lentil Crumbles, FDA Investigates - MedicineNet Health NewsFallout is mounting for the food delivery service Daily Harvest, which has voluntarily recalled a frozen food product suspected of sickening hundreds of customers in at least 26 states.
Read more »
FDA Warns Against Baby Neck Floats After A Reported DeathThe organization urged caregivers to stop using inflatable neck floats, especially with babies who have developmental delays or special needs.
Read more »
FDA temporarily suspends order banning Juul cigarettesThe Food and Drug Administration has issued a stay of its recent order for vaping company Juul to pull its electronic cigarettes from the market. The FDA says the stay is temporary while it conducts further review.
Read more »
'Unique' Issues Cause FDA To Temporarily Suspend Ban On Juul CigarettesThe FDA issued the initial order banning Juul sales on June 23. A day later, a federal appeals court temporarily blocked the government ban.
Read more »
FDA temporarily suspends order banning Juul cigarettesThe Food and Drug Administration said on Twitter that the stay temporarily suspends the marketing denial order while it conducts further review, but does not rescind it.
Read more »
FDA decision on Eisai, Biogen Alzheimer's drug due in JanuaryThe U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd's and Biogen Inc's experimental Alzheimer's drug lecanemab, with a decision due by Jan 6, 2023, the companies said on Tuesday.
Read more »